Pando Software Begins Pre-Registration of Three New P2E Pandonia Universes
The new P2E Pandonia Universe starts pre-registration ahead of its simultaneous worldwide release. The three Pandonia Universes include ‘Pandonia Arena,’ ‘Guardians of Pandonia,’ and ‘Dragons of Pandonia.’ Pre-registration is available now on https://pandonia.co.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426006357/en/
Three new P2E Pandonia Universes have started pre-registration ahead of their worldwide release. The three Pandonia Universes include ‘Pandonia Arena,’ ‘Guardians of Pandonia,’ and ‘Dragons of Pandonia.’ Pre-registration is available now on the official website. (Graphic: Business Wire)
‘Pandonia Arena’ with unique heroes
‘Pandonia Arena’ was issued as non-fungible tokens (NFT) for heroes with distinctive visuals and unique skills. The control method that allows anyone to play easily, such as battle royale mode, big boss mode, and crown mode, is a huge advantage. The global No.1 Arcade NFT-based P2E game ‘Pandonia Arena’ will be released in May.
New collectible RPG, P2E game ‘Guardians of Pandonia’
‘Guardians of Pandonia’ is a mobile collectible RPG where you can create your own team with up to six characters and enjoy adventures, raids, and PvP content. In particular, there are high expectations for this new collectible P2E game in Japan, so it is planned to be released in June.
MMORPG 'Dragons of Pandonia,' a story created with a variety of dragons
‘Dragons of Pandonia’ is an MMORPG focused on dragons. It is the P2E-based MMORPG where users write their own huge and powerful stories relying on five different occupation types and various dragons. Development is underway aiming at a global launch in July.
Special benefits for pre-registrants of the three Pandonia Universes
For pre-registered users, Pando Software has announced that it will provide game-related privileges along with an airdrop event in which 10,000 mPANDO will be drawn and distributed, fitting the game's official release date.
In the three new Pandonia Universes, users can acquire mPANDO through gameplay as well as through other games currently being serviced by Pando Software. mPANDO is a MainNet coin and is designed to be used for various in-game applications.
Starting with the ‘Legend of Pandonia’ as its first P2E project in 2022, Pando Software has continued with the ‘I Love Pandonia’ release to the global market.
The detailed schedule and news about the three Pandonia Universes can be checked on the official website (https://pandonia.co).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006357/en/
Contact information
Pando Software Inc
Lucia Tanti
+82-70-5100-0815
pr@pandosoft.co.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom